1 of 1
With the launch of Europe’s first adalimumab (Humira) biosimilars in October of 2018, leaders at AbbieVie faced tough questions from stakeholders and analysts during their Q3 earnings call. Ex-US sales erosion for the world’s best-selling drug is now projected to be higher than initially anticipated, due at least in part to discounting for the new wave of adalimumab biosimilars also being higher than the company’s initial projections predicted. Find out more about the impact of EU adalimumab on AbbieVie’s bottom line in this article from Scrip.
Note: Product cover images may vary from those shown